The use of AI in drug development and regulation was a hot topic among speakers and attendees at the RAPS Euro Convergence 2024 meeting, held on 6-8 May in Berlin, Germany. Industry representatives shared many examples of how the use of AI was now widespread throughout the drug R&D process, while regulators provided updates on their own efforts to keep pace with the growing use of this technology.
Florian Lasch, a biostatistics specialist at the European Medicines Agency, said during a panel discussion on 7 May that the...








